Reason for request
Inclusion on the list of medicines approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit is substantial. |
Clinical Added Value
| important |
In view of the results obtained in a population with an unfavourable prognosis and the size of the effect observed, the Transparency Committee considers that TORISEL provides a substantial improvement in actual benefit (IAB level II) compared with interferon alpha (ROFERON-A) in advanced renal cell carcinoma patients with at least 3 of the 6 prognostic risk factors. |
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
mwm4Hv9m83ujyUY6
